Clinical proteomics: Insights from IGF-I
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Clinical proteomics : Insights from IGF-I. / Albrethsen, Jakob; Frederiksen, Hanne; Johannsen, Trine Holm; Andersson, Anna-Maria; Juul, Anders.
I: Clinica chimica acta; international journal of clinical chemistry, Bind 477, 2018, s. 18-23.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Clinical proteomics
T2 - Insights from IGF-I
AU - Albrethsen, Jakob
AU - Frederiksen, Hanne
AU - Johannsen, Trine Holm
AU - Andersson, Anna-Maria
AU - Juul, Anders
N1 - Copyright © 2017 Elsevier B.V. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.
AB - Clinical proteomics aims to deliver cost-effective multiplexing of potentially hundreds of diagnostic proteins, including distinct protein isoforms. The analytical strategy known as targeted proteomics is particularly promising because it is compatible with robust mass spectrometry (MS)-platforms already implemented in many clinical laboratories for routine quantitation of small molecules (i.e. uHPLC coupled to triple-quadrupole MS). Progress in targeted proteomics of circulating insulin-like growth factor 1 (IGF-I) have provided valuable insights about tryptic peptides, transitions, internal standards and calibrants. The present challenge is to examine if targeted proteomics of IGF-I can truly measure up to the routine performance that must be expected from a clinical testing platform.
KW - Chromatography, High Pressure Liquid
KW - Humans
KW - Insulin-Like Growth Factor I/analysis
KW - Mass Spectrometry
KW - Protein Isoforms
KW - Proteomics
U2 - 10.1016/j.cca.2017.11.034
DO - 10.1016/j.cca.2017.11.034
M3 - Review
C2 - 29196187
VL - 477
SP - 18
EP - 23
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -
ID: 217615453